Relay Therapeutics points to drug price negotiations for delay in potential blockbuster cancer drug
While it may ultimately be impossible to verify why exactly a clinical-stage biotech would delay a potential new drug approval, Relay Therapeutics said yesterday that it will push back seeking approval for its potential FGFR2 selective inhibitor RLY-4008 (lirafugratinib) in bile duct cancer to wait for a larger indication because of incoming government drug price negotiations.
The decision comes as the company also announced yesterday promising new data for lirafugratinib in patients with FGFR2-altered solid tumors, demonstrating activity across several sub-groups, including patients with FGFR2-fusion tumors and patients with FGFR2-altered HR+/HER2- breast cancer, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.